Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
复制标题
卡培他滨治疗后的手足综合征是否与转移性乳腺癌患者更好的预后相关？
DOI：
10.1080/02841860600791509
复制
发表时间：
2006
期刊：
影响因子：
3.1
通讯作者：
N. Guler
中科院分区：
文献类型：
--
作者：
M. Kurt;S. Aksoy;N. Guler
疾病进展率和稳定率分别为21%和28%。中位总生存期为17.5个月（95% CI：11.723.3），中位无进展生存期（PFS）为6.7个月（95% CI：4.98.6）。94例患者中有55例（59%）发生了HFS，而31%的患者发生了需要降低剂量的不良反应。在发生HFS的患者中，42%有3级毒性。他们的中位PFS为7.1个月（95% CI：5.38.9），而无HFS的患者为4.3个月（95% CI：2.26.4）（p /0.058）（图1）。然而，两组之间的总生存率差异不显著（表I）。12级HFS患者的中位PFS为6.4个月（95% CI：
progressive and stabile disease rates were 21% and 28%, respectively. The median overall survival was 17.5 months (95% CI: 11.723.3) and the median progression free survival (PFS) was 6.7 months (95% CI: 4.98.6). Fifty-five of the 94 patients (59%) developed HFS, while adverse reactions requiring dose reduction occurred in 31% of patients. In those who developed HFS, 42% had grade 3 toxicity. Their median PFS was 7.1 months (95% CI: 5.38.9), when compared to the 4.3 months (95% CI: 2.26.4) in those who did not have HFS (p /0.058) (Figure 1). The difference in overall survival between the two groups, however, was insignificant (Table I). Patients with grade 12 HFS had a median PFS of 6.4 months (95% CI: